Human protein C concentrate in pediatric septic patients

Giovanni Landoni, Giacomo Monti, Alberto Facchini, Francesco Cama, Elena Bignami, Luca Cabrini, Federico Pappalardo, Alberto Zangrillo

Research output: Contribution to journalArticlepeer-review


Severe sepsis and septic shock are leading causes of morbidity and mortality in the pediatric population. Unlike what is suggested for the adult population, recombinant human activated protein C (rhAPC) is contraindicated in children. Long before rhAPC was considered for use in pediatric patients, case reports appeared on the safe administration of protein C zymogen. Therefore, we conducted a systemic review of currently available data on protein C zymogen (PC) use among children affected by severe sepsis or septic shock. A total number of 13 case series or case reports and a dose-finding study were found on the use of PC in the pediatric intensive care unit, reporting on 118 treated children, with an overall survival of 84%. There was no bleeding complication, the only reported complication being a single mild allergic reaction These studies show that PC is safe, not associated with bleeding and possibly useful for improving coagulation abnormalities of sepsis.

Original languageEnglish
Pages (from-to)13-19
Number of pages7
JournalSigna Vitae
Issue number1
Publication statusPublished - 2010


  • Drug therapy
  • Pediatric
  • Protein C
  • Review
  • Sepsis

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine


Dive into the research topics of 'Human protein C concentrate in pediatric septic patients'. Together they form a unique fingerprint.

Cite this